Kinesiophobia in Rheumatoid Arthritis: Associations With Functional Disability, Disease Activity, and Related Clinical Factors

Objectives: Impairment of physical function is a core feature of RA, particularly in patients with high disease activity where pain and inflammation directly limit movement. but, Reduced mobility in RA is not exclusively driven by inflammatory pathology. There are non-inflammatory factors, including kinesiophobia, fatigue, depression, and anxiety, may significantly contribute to functional limitation and may initiate a self-perpetuating cycle in which movement avoidance leads to physical deconditioning, muscle weakness, and progressive functional decline. The aim of this study is to examine the relationship between kinesiophobia and functional outcomes in patients with rheumatoid arthritis, and to investigate its associations with disease activity, pain, fatigue, depressive symptoms, anxiety, and sarcopenia, with a focus on factors relevant to functional assessment and rehabilitation.

Patients and Methods

A case - control study will be conducted on Two hundred adult patients previously diagnosed with RA according to ACR/EULAR 2010 criteria for RA and 200 apparently healthy volunteers with age and sex matching will be involved in the study. The study will be conducted in Rheumatology department, Minia university Hospital, Egypt. All patients will be subjected to history taking, clinical examination, and assessment of the following parameters:

1. Kinesiophobia: using the Arabic version of TSK-17
2. Disease activity: using DAS 28
3. pain severity using the Visual Analogue Scale (VAS)
4. Fatigue: using the Arabic version of the Fatigue Severity Scale (FSS)
5. Depression: using the Arabic version of the BDI-2
6. Anxiety: using the Arabic version of the BAI
7. sarcopenia using the Arabic version of the SARC-F questionnaire
8. Functional disability: using the Arabic version of the HAQ-DI
9. Physical activity:using IPAQ-SF

Study Overview

• Status: Not yet recruiting
• Conditions: Rheumatoid Arthritis (RA); Rheumatoid; Rhematoid Arthritis; Kinesiophobia (Fear of Movement)

Detailed Description

Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease affecting approximately 0.5-1% of the global population. It is characterized by persistent synovial inflammation leading to progressive cartilage and bone destruction, resulting in functional impairment and substantial physical, social, and psychological burden.

Impairment of physical function and mobility is a core feature of RA, particularly in patients with high disease activity or advanced joint damage, where pain and inflammation directly limit movement and daily activities.

However, reduced mobility in RA is not exclusively driven by inflammatory pathology. Increasing evidence suggests that non-inflammatory factors, including kinesiophobia, fatigue, depression, and anxiety, may significantly contribute to functional limitation.

Kinesiophobia, defined as an excessive and irrational fear of movement related to pain or perceived risk of injury, constitutes a major challenge for patients with RA. This condition may initiate a self-perpetuating cycle in which movement avoidance leads to physical deconditioning, muscle weakness, and progressive functional decline. Such fear often arises from maladaptive interpretations of pain as a harmful sensory experience, resulting in avoidance behaviors and dysfunctional pain-related cognitions.

In RA, altered pain-related cognitive processing and heightened fear responses appear particularly relevant, contributing to increased kinesiophobia as disease severity progresses. Importantly, elevated disease activity does not necessarily indicate the presence of kinesiophobia, as some patients may experience pain-related functional impairment in the absence of fear of movement. Conversely, kinesiophobia may develop in patients with low disease activity or minimal joint destruction, in whom fear itself-rather than active inflammation-becomes the principal driver of movement avoidance and disability.

Several studies have demonstrated associations between kinesiophobia and disease activity, pain, fatigue, depressive symptoms, and anxiety in RA. These interrelated factors may reinforce fear-based avoidance behaviors that are not fully explained by objective inflammatory burden. Depression and fatigue are common non-inflammatory manifestations of RA and are closely linked to disease burden and functional impairment, further contributing to reduced physical activity. Anxiety is also highly prevalent in RA and has been identified as an important contributor to fear of movement, even among patients with relatively low disease activity.

In addition, sarcopenia has emerged as a clinically relevant comorbidity in RA. Recognized as a distinct clinical entity in the ICD-10 since 2016 in accordance with the European Working Group on Sarcopenia in Older People )EWGSOP2( recommendations, sarcopenia is characterized by reduced muscle mass and strength with impaired physical performance. It may be primary (age-related), typically manifesting in individuals aged 70 years and older, or secondary to chronic inflammatory conditions such as RA. Its reported prevalence ranges from 3% to 24% depending on diagnostic criteria and increases with age, although it is increasingly recognized in younger patients with autoimmune diseases. In RA, sarcopenia affects approximately 20-30% of patients and is associated with greater disease severity and poorer functional outcomes.

Collectively, these findings underscore kinesiophobia as a multidimensional, non-inflammatory factor interacting with inflammatory, psychological, and musculoskeletal components of RA. This highlights the importance of systematically assessing kinesiophobia to better understand functional outcomes and to inform comprehensive, rehabilitation-oriented management strategies.

Methods:

All patients will be subjected to:

1. Full history taking and clinical examination.
2. Disease activity: the disease activity will be evaluated by disease activity score 28 (DAS 28).

3. Kinesiophobia:

   The TSK-17 will be used as it represents the original validated version and has been culturally adapted and validated in Arabic populations. This questionnaire consists of 17 items. Each item is rated on a four-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree). The total score is calculated after inversion of the scores of items 4, 8, 12 and 16 yielding a total score between 17 and 68, where higher scores reflect greater fear of movement-related pain. A score of 37 differentiates between high and low scores. The scale is simple to administer, does not require specialized training, and involves no additional cost.

4. Pain: pain severity will be measured using Visual Analogue Scale (VAS).

5. Fatigue:

   The Arabic version of Fatigue Severity Scale (FSS) will be used. FSS includes 9 items that evaluate fatigue severity in the past week. Each item is scored between 1 (strongly disagree) and 7 (strongly agree). The average score of the 9-items represents the FSS total score. Higher scores indicate more severity.

6. Depression:

   The Arabic version of 21-item Beck Depression Inventory (BDI) will be used to assess depressive symptoms. Each item is scored ranging from 0 to 3, then the total BDI score is calculated by summing the scores of all items. The total score will range from 0 to 63, with higher scores reflecting greater severity of depression.

7. Anxiety:

   The Arabic version of the Beck Anxiety Inventory (BAI) will be utilized to assess anxiety symptoms. It is self-report questionnaire consisting of 21 items with good validity and reliability. Each item is scored from 0 to 3 with calculating the total score by finding the sum of the 21 items. Score of (0-21) = low anxiety, Score of (22-35) = moderate anxiety and Score of (36 and above) = potentially concerning levels of anxiety.

8. Sarcopenia:

   Assessment of sarcopenia will be done using the Arabic version of the SARC-F questionnaire. The SARC-F includes questions on five items: strength, assistance in walking, rising from a chair, climbing stairs, and falls. Each item is scored from 0 to 2 points, with a total score of 10 points. Total scores ≥4 indicates sarcopenia.

9. Functional disability:

   The Arabic version of Health Assessment Questionnaire Disability Index (HAQ-DI) will be used. The HAQ-DI includes 8 domains (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities) and 20-items were used measuring functional disability over the past week. Each item is scored between 0 (without difficulty) and 3 (unable to do). The highest sub-category score represents each domain score. The total HAQ-DI score is the average score of eight domains that ranges between 0 and 3. higher scores means more disability.

10. Physical activity:

The Arabic version of The International Physical Activity Questionnaire - Short Form (IPAQ-SF) will be used to assess physical activity. IPAQ-SF is a widely used, 9-item self-report tool that measures activity levels in adults (15-69 years) across walking, moderate-intensity and vigorous-intensity activities, estimating MET-minutes per week for overall activity and sitting time.

• Study Type: Observational
• Enrollment (Estimated): 400

Contacts and Locations

• Study Contact: Name: Marwa Abdelhakim Shaban Maghlouf, Resident Doctor; Phone Number: +201154704022; Email: marwat.shaeban422@med.s-mu.edu.eg
• Study Contact Backup: Name: Ahmed Elsayed Hafez, Assistant Professor; Phone Number: +201101013625

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Two hundred adult patients previously diagnosed with RA according to ACR/EULAR 2010 criteria for RA and 200 apparently healthy volunteers with age and sex matching will be involved in the study.

All patients included in this study will be verbally briefed about the details and the nature of the study & will sign a written informed consent according to the local Ethics Committee of Minia University Faculty of Medicine.

The study will be conducted in Rheumatology department, Minia university Hospital, Egypt.

Description

Inclusion Criteria:

• Age: adult population with RA (18-69)
• Disease duration ≥ 6 months

Exclusion Criteria:

1. Juvenile cases
2. Other rheumatic diseases (SLE, AS, 1ry OA, etc.)
3. Trauma
4. Comorbidities that affect mobility, e.g., UMNL (including stroke), parkinsonism, multiple sclerosis, cerebral palsy, dementia, peripheral neuropathy, chronic pain conditions, etc.
5. Previous history of psychiatric illness before onset of RA (anxiety, depression, etc.)
6. Pregnancy and lactation

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Grpoup 1; Two hundred adult patients previously diagnosed with RA according to ACR/EULAR 2010 criteria for RA
Group 2; 200 apparently healthy volunteers with age and sex matching

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
examine the relationship between kinesiophobia and rheumatoid arthritis	examine the correlation between kinesiophobia and functional outcomes in patients with rheumatoid arthritis, and to investigate correlations of Tampa Scale of Kinesiophobia with 1- disease activity using DAS28 2, pain using VAS 3, fatigue using FSS 4, depressive symptoms using BDI II 5, anxiety using BAI 6, sarcopenia using SARC-F 7, functional disability using HAQ-DI 8. and physical activity using IPAQ-SF AA, with a focus on factors	Baseline

Collaborators and Investigators

• Sponsor: Minia University
• Investigators: Principal Investigator: Ahmed Elsayed Hafez, Assistant Professor, Rheumatology, Rehabilitation and Physical Medicine department, Faculty of Medicine, Minia University; Study Chair: Rasha Samir Refaat, Assistant Professor, Psychiatry Department, Faculty of Medicine, Minia University; Study Chair: Walaa Fawzy Mohamed, Lecturer, Rheumatology, Rehabilitation and Physical Medicine department, Faculty of Medicine, Minia University

Publications and helpful links

General Publications

• 34. Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381-1395.
• 33. Al-Hazzaa HM. Reliability and validity of the Arabic version of the International Physical Activity Questionnaire (IPAQ). Annals of Saudi Medicine. 2007;27(6):429-435
• 32. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14:531-532.
• 31. Alqahtani BA, Alenazi AM, Alshehri MM, et al. Cross-cultural adaptation and validation of the Arabic version of the SARC-F questionnaire for evaluating sarcopenia in Saudi older adults. BMC Geriatr. 2025;25(1):773. doi:10.1186/s12877-025-06349-y.
• 30. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893-897.
• 29. Al-Rumaih M, Abdel-Khalek A. Differentiation between anxiety and depression using cognitive and affective models. J Psychol Stud. 2002;12:541-578.
• 28. Al-Shatti TS. Psychometric properties of the Arabic version of the Beck Anxiety Inventory in Kuwait. J Educ Psychol Sci. 2015;16:431-463.
• 27. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio: Psychological Corporation; 1996.
• 26. Farhood LF, Dimassi H. Validation of an Arabic version of the GHQ-28 against the Beck Depression Inventory for screening for depression. Psychol Rep. 2015;116(2):470-484.
• 25. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-1123.
• 24. Al-Sobayel HI, Al-Hugail HA, AlSaif RM, et al. Validation of an Arabic version of the Fatigue Severity Scale. Saudi Med J. 2016;37(1):73-78. doi:10.15537/smj.2016.1.13055.
• 23. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol. 2003;30(1):167-178.
• 22. El Meidany YM, El Gaafary MM, Ahmed I. Adaptation and validation of an Arabic version of the Health Assessment Questionnaire for patients with rheumatoid arthritis. Rev Rhum Engl Ed. 2003;70(5):401-407.
• 21. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983;17:45-56.
• 20. Miller R, Kori S, Todd D. The Tampa Scale: a measure of kinesiophobia. Clin J Pain. 1991;7(1):51-52.
• 19. Vlaeyen JWS, Kole-Snijders AMJ, Boeren RGB, van Eek H. Fear of movement/(re)injury in chronic low back pain and its relation to behavioral performance. Pain. 1995;62(3):363-372.
• 18. Malik Juweid K, Farah K, Hawamdeh Z, Alqudah A, Nowlin L, Vlaeyen JWS, Trost Z. Establishing the validity of the Arabic version of the Tampa Scale of Kinesiophobia. Myopain. 2017. doi:10.1080/24708593.2017.1303014.
• 17. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation. Arthritis Rheum. 1995;38(1):44-48.
• 16. Tournadre A, Vial G, Capel F, Soubrier M, Boirie Y. Sarcopenia. Joint Bone Spine. 2019;86(3):309-314.
• 15. Moschou D, Krikelis M, Georgakopoulos C, et al. Sarcopenia in rheumatoid arthritis: a narrative review. J Frailty Sarcopenia Falls. 2023;8(1):44.
• 14. Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review. Psychol Med. 2013;43(3):471-481.
• 13. Lopes FHA, Freitas MVC, de Bruin VMS, de Bruin PFC. Depressive symptoms are associated with impaired sleep, fatigue, and disease activity in women with rheumatoid arthritis. Adv Rheumatol. 2021;61(1):18.
• 12. Reinoso-Cobo A, Ortega-Avila AB, Ramos-Petersen L, et al. Relationship between kinesiophobia and disease activity in patients with rheumatoid arthritis. Medicina (Kaunas). 2023;59(1):147. doi:10.3390/medicina59010147.
• 11. Baday-Keskin D, Ekinci B. The relationship between kinesiophobia and health-related quality of life in patients with rheumatoid arthritis: a controlled cross-sectional study. Joint Bone Spine. 2022;89(2):105275.
• 10. Edwards RR, Cahalan C, Mensing G, Smith M, Haythornthwaite JA. Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol. 2011;7:216-224.
• 9. Öztürk IB, Garip Y, Sivas F, Özden MP, Bodur H. Kinesiophobia in patients with rheumatoid arthritis: relationship with muscle strength, fear of falling, disease activity, and quality of life. Arch Rheumatol. 2021;36(3):427.
• 8. Yildirim N. Comparison of kinesiophobia in patients with rheumatoid arthritis and systemic lupus erythematosus. Eur Rev Med Pharmacol Sci. 2023;27(23).
• 7. Alwhaibi M. Depression, anxiety, and health-related quality of life in adults with rheumatoid arthritis: findings from a national survey. J Clin Med. 2025;14(22):7940. doi:10.3390/jcm14227940.
• 6. Xueying S, Yanli Y, Wei X, Lingling Z, Lili L. Influence of kinesiophobia on activity, function, and anxiety levels in patients with rheumatoid arthritis. Front Med. 2025;11:1514088. doi:10.3389/fmed.2024.1514088.
• 5. Verhoeven F, Tordi N, Prati C, Demougeot C, Mougin F, Wendling D. Physical activity in patients with rheumatoid arthritis. Joint Bone Spine. 2016;83(3):265-270. doi:10.1016/j.jbspin.2015.10.002.
• 4. Garip Y, Eser F, Bodur H. Comorbidities in Turkish patients with rheumatoid arthritis and their association with health-related quality of life. Acta Reumatol Port. 2016;41(4):344-349.
• 3. Kınıklı GI, Deniz HG, Karahan S, Ateş A, Turgay M, Kınıklı G. Predictors of fear of movement in patients with rheumatoid arthritis. Fizyoter Rehabil. 2018;29(2):11-17.
• 2. Gravallese EM, Firestein GS. Rheumatoid arthritis: common origins, divergent mechanisms. N Engl J Med. 2023;388(6):529-542. doi:10.1056/NEJMra2103726.
• 1. Akar BEGUM, Calik BB, Kabul EG, Akbas ANB, Çobankara V. Examining the presence of sarcopenia in women with rheumatoid arthritis: a case-control study. Rom J Intern Med. 2024;62(2):150-159.

Study record dates

Study Major Dates

• Study Start (Estimated): March 1, 2026
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): October 1, 2026

Study Registration Dates

• First Submitted: February 20, 2026
• First Submitted That Met QC Criteria: February 20, 2026
• First Posted (Actual): February 27, 2026

Study Record Updates

• Last Update Posted (Actual): March 3, 2026
• Last Update Submitted That Met QC Criteria: February 27, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Depression; Pain; Anxiety; Fatigue; Rheumatoid Arthritis; sarcopenia; Kinesiophobia; Disease Activity; Functional Disability; Fear of Movement
• Additional Relevant MeSH Terms: Neurologic Manifestations; Musculoskeletal Diseases; Nervous System Diseases; Neuromuscular Manifestations; Mental Disorders; Pathological Conditions, Anatomical; Arthritis; Joint Diseases; Rheumatic Diseases; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Behavioral Symptoms; Muscular Atrophy; Atrophy; Phobic Disorders; Pathological Conditions, Signs and Symptoms; Behavior; Skin and Connective Tissue Diseases; Signs and Symptoms; Kinesiophobia; Pain; Anxiety Disorders; Depression; Fatigue; Arthritis, Rheumatoid; Sarcopenia
• Other Study ID Numbers: Kinesiophobia in RA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No